Reverse-Payment Settlements: What Now? – A Discussion on the Implications of the FTC v. Actavis and Lundbeck Decisions

Skadden recently hosted a webinar – "Reverse-Payment Settlements: What Now?" – with presenters from the firm's antitrust and intellectual property litigation groups. Listeners received an overview of the recent U.S. Supreme Court decision in FTC v. Actavis, Inc. and the European Commission decision in Lundbeck, both of which addressed the antitrust standards to be applied to reverse-payment pharmaceutical patent litigation settlements.

Read key takeaways here.

Access a recording of the webinar here.